Medpace Holdings Inc vs Toyota Motor Corp — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Toyota Motor Corp trades at $188.07 (market cap $221.79B). The key difference: Toyota Motor Corp is far larger — about 13.1× Medpace Holdings Inc's market cap, and Toyota Motor Corp pays a 3.3% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TM | |
|---|---|---|
Market Cap | $16.90B | $221.79B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $248.29 |
52-Week Low | $393.42 | $166.50 |
Enterprise Value | $16.52B | $414.06B |
Dividend Yield | — | 3.3% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Toyota Motor trades at $188.22, down 0.3% over 24 hours, with a bullish technical signal and strong fundamentals including a low P/E of 8.53 and consistent earnings beats. Recent news highlights a major vehicle recall and mixed quarterly results, with revenue growth offset by cost pressures.
The outlook is cautiously optimistic given attractive valuation and hybrid vehicle strength, but risks include recall costs, China sales weakness, and macroeconomic headwinds. Analyst consensus leans Hold, reflecting balanced growth prospects against near-term challenges.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →